Crossmark

A nasal vaccine candidate based on S2 and N proteins from SARS-CoV-2 generates a broad antibody response systemically and in the lower respiratory tract

Crossref DOI link: https://doi.org/10.1007/s12026-025-09675-w

Published Online: 2025-08-27

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lobaina, Yadira

Chen, Rong

Vazquez-Blomquist, Dania

Suzarte, Edith

Zhang, Miaohong

Zhou, Zhiqiang

Lan, Yaqin

Guillen, Gerardo

Li, Wen

Perera, Yasser

Hermida, Lisset
Funding

Funding for this research was provided by:

Hunan Provincial Base for Scientific and Technological Innovation Cooperation (2019CB1012)

The Science and Technology Innovation Program of Hunan Province (2020RC5035)

Hunan Provincial Innovative Construction Program (2020WK2031)

MOST “National key R&D program of China (2021YFE0192200)
License Information

Text and Data Mining valid from 2025-08-27

Version of Record valid from 2025-08-27
More Information

Article History

Received: 15 May 2025

Accepted: 5 August 2025

First Online: 27 August 2025

Declarations

:

: Clinical trial number: not applicable. The animal study protocols were approved by the Institutional Animal Care and Use Committee at Beijing Vital River Laboratory Animal Technology Co., Ltd. and Hunan PRIMA Animal facility. The standard of laboratory animal room complied with the national standard of the people’s Republic of China GB14925-2010. Protocols: PANCOV03 (approved on March 2022) and HNSE2023(3)049 (approved on July 2023).

: All authors have consented to publish the manuscript.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below